Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trialPaul A. Richardson, Trần Việt Hà, Estelle Piwowar‐Manning et al.|UNC Libraries|2025Cited by 1
Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenPatrick S. Sullivan, Lucy E. Cottle, B. Grinsztejn et al.|UNC Libraries|2023Cited by 0